

## DESCRIPTION


<b>Species Reactivity</b>	Human
<b>Specificity</b>	Detects human LILRA5/CD85f in direct ELISAs. In direct ELISAs, approximately 7% cross-reactivity with recombinant human LILRA4 is observed.
<b>Source</b>	Polyclonal Sheep IgG
<b>Purification</b>	Antigen Affinity-purified
<b>Immunogen</b>	Chinese hamster ovary cell line CHO-derived recombinant human LILRA5/CD85f Gly42-Arg268 Accession # A6NI73
<b>Formulation</b>	Lyophilized from a 0.2 µm filtered solution in PBS with Trehalose. See Certificate of Analysis for details. *Small pack size (-SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.

## APPLICATIONS

**Please Note:** Optimal dilutions should be determined by each laboratory for each application. [General Protocols](#) are available in the Technical Information section on our website.

	Recommended Concentration	Sample
<b>Flow Cytometry</b>	2.5 µg/10 <sup>6</sup> cells	See Below
<b>CytoF-ready</b>	Ready to be labeled using established conjugation methods. No BSA or other carrier proteins that could interfere with conjugation.	
<b>Blockade of Receptor-ligand Interaction</b>	In a functional ELISA binding assay, 1-7 µg/mL of this antibody will block 50% of the binding of 1 µg/mL of Recombinant Human Angiotensin-like 7 (Catalog # 914-AN) to immobilized Recombinant Human LILRA5/CD85f/LIR-9 (Catalog # 8956-T4) coated at 2 µg/mL (100 µL/well). At 15 µg/mL, this antibody will block >90% of the binding.	

## DATA



## PREPARATION AND STORAGE

<b>Reconstitution</b>	Sterile PBS to a final concentration of 0.2 mg/mL.
<b>Shipping</b>	The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. *Small pack size (-SP) is shipped with polar packs. Upon receipt, store it immediately at -20 to -70 °C
<b>Stability &amp; Storage</b>	<b>Use a manual defrost freezer and avoid repeated freeze-thaw cycles.</b> <ul style="list-style-type: none"> <li>• 12 months from date of receipt, -20 to -70 °C as supplied.</li> <li>• 1 month, 2 to 8 °C under sterile conditions after reconstitution.</li> <li>• 6 months, -20 to -70 °C under sterile conditions after reconstitution.</li> </ul>

## BACKGROUND

ILT11 (leukocyte immunoglobulin-like receptor 9; also CD85f, LIR-9 and LILRA5) is a 39-40 kDa Group 2 member of the LILR family of innate immune receptors. It is expressed on monocytes and perhaps neutrophils, and its activation results in the secretion of proinflammatory cytokines such as TNF-α and IL-1β. Mature human LIR-9 is a 258 amino acid (aa) type I transmembrane glycoprotein. It has a 227 aa extracellular domain (aa 42-268) that contains two C2-type Ig-like domains (aa 51-136 and 142-230), and a 10 aa cytoplasmic tail. LIR-9 has three potential splice forms. One is a 35 kDa soluble form of the molecule described above that shows a 27 aa substitution for aa 239-299. The other two splice forms are analogous to the above membrane and soluble forms, but demonstrate signal sequence cleavage further downstream after Ala51. Over aa 41-268, human LIR-9 shares 58% aa identity with mouse LIR-9.